Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL6000241

CCC(c1ccncc1)c1cccc(F)c1.N

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 4/20 0.51
PDE4A P27815 1/20 0.45
CYP19A1 P11511 2/20 0.43
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
S1PR1 P21453 1/20 0.41
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CYP3A4 P08684 1/20 0.40
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
IDO1 P14902 1/20 0.38
TDO2 P48775 1/20 0.38
AOC3 Q16853 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL5999540 0.88 IDO1 (0.47) CYP19A1SLC6A2SLC6A4IDO1TDO2
Ammonia Solution, Strong SCHEMBL6001307 0.88 IDO1 (0.46) CYP19A1SLC6A2SLC6A4IDO1TDO2
SCHEMBL23126406 0.86 IDO1 (0.49) CYP19A1SLC6A2SLC6A4IDO1TDO2
SCHEMBL22048343 0.86 IDO1 (0.47) CYP19A1SLC6A2SLC6A4IDO1TDO2
Ammonia Solution, Strong SCHEMBL5999961 0.85 CYP17A1 (0.54) CYP17A1PDE4ASLC6A2SLC6A4SLC6A3
Ammonia Solution, Strong SCHEMBL5999992 0.84 CYP19A1 (0.45) CYP19A1SLC6A2SLC6A4SLC6A3
Methylamine SCHEMBL6900406 0.83 IDO1 (0.50) CYP19A1SLC6A2SLC6A4IDO1TDO2
Ammonia Solution, Strong SCHEMBL6001477 0.83 IDO1 (0.42) CYP19A1SLC6A2SLC6A4IDO1TDO2
SCHEMBL21910600 0.83 IDO1 (0.42) CYP17A1CYP19A1SLC6A2SLC6A4IDO1
Methylamine SCHEMBL6000383 0.83 IDO1 (0.49) CYP19A1SLC6A2SLC6A4IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885PDE4A 3399/4885CYP19A1 4624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.